PALI Share Price Performance
US$1.01
-2.50 (-71.23%)
Price US$1.01
Share PriceUS$1.01
PALI Community Narratives
There are no narratives available yet.
Recent PALI News & Updates
No updates
Palisade Bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.74
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Palisade Bio, Inc. Competitors
About PALI
- Founded
- n/a
- Employees
- 8
- CEO
- WebsiteView website
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading